Spevatamig (PT886) for Advanced Gastric, Pancreatic, or Biliary Tract Cancers

This study is testing a new drug called Spevatamig (PT886) for advanced gastric (stomach), gastroesophageal junction (where the esophagus meets the stomach), pancreatic, or biliary tract (bile duct) cancers. Spevatamig (PT886) is a bispecific antibody, meaning it targets two specific proteins (Claudin 18.2 and CD47) on cancer cells. You might receive Spevatamig (PT886) alone or in combination with chemotherapy drugs like Paclitaxel, Gemcitabine, and Abraxane, or with an immunotherapy drug called KEYTRUDA® (pembrolizumab). The main goals are to see how safe Spevatamig (PT886) is, how well you tolerate it, and if it can shrink tumors. This study is open to adults aged 18 and older who have measurable disease and have been previously treated for their cancer. The study plans to enroll 258 participants.

Study design
This is a Phase 1/2, open-label study, meaning both you and your doctors will know which treatment you are receiving. It involves different groups to test Spevatamig (PT886) alone and in various combinations.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Your safety, tolerability, and anti-tumor activity will be evaluated through study completion, which is an average of 2 years.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT05482893

Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or ICI, for the Treatment of Patients With Advanced Gastric, Gastroesophageal Junction, Pancreatic Ductal or Biliary Tract Carcinomas (the TWINPEAK Study)

Recruiting
PHASE1Ages 18+InterventionalTreatment
Phanes Therapeutics
~258 participants
Updated 2026-07-09 on ClinicalTrials.gov
What's tested:Spevatamig (PT886)PaclitaxelGemcitabineAbraxaneKEYTRUDA® (pembrolizumab)FOLFOX

At a glance

Recruiting sites
10 of 11 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
To evaluate the safety and tolerability of Spevatamig (PT886) as monotherapy and in each individual combination substudy.
Measured over Through study completion, an average of 2 years
+2 more outcomes measured
Gastric or Gastroesophageal Junction Adenocarcinoma
Pancreatic Ductal Adenocarcinoma
Biliary Tract Cancer (BTC)

NCT05482893

Where you'd take part

This study runs at 11 sites. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • City of Hope (City of Hope National Medical Center, City of Hope Medical Center)

    Duarte, Californiano site contact published

    Recruiting

  • Duke Cancer Center

    Durham, North Carolinano site contact published

    Recruiting

  • MD Anderson Cancer Center, GI Medical Oncology Dept

    Houston, Texasno site contact published

    Recruiting

  • NEXT Oncology

    Fairfax, Virginiano site contact published

    Recruiting

  • Norton Cancer Institute

    Louisville, Kentuckyno site contact published

    Recruiting

  • Sarah Cannon Research Institute (SCRI)

    Denver, Coloradono site contact published

    Recruiting

  • University of Iowa

    Iowa City, Iowano site contact published

    Recruiting

  • University of Pittsburgh Medical Center (UPMC)

    Pittsburgh, Pennsylvaniano site contact published

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Opens a ready-to-send draft in your own email app — review before sending.

  • To evaluate the safety and tolerability of Spevatamig (PT886) as monotherapy and in each individual combination substudy.Through study completion, an average of 2 years
  • To evaluate anti-tumor activity of PT886 as assessed by ORR, in Spevatamig (PT886) monotherapy and in each combination substudy.Through study completion.
  • To determine the recommended dose for expansion of Spevatamig (PT886) monotherapy.Through study completion.